Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZenoParticle CH-100
- Development stage
- Preclinical
- Lead developer
- Zenoaq Resource
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous, Intradermal, Intraperitoneal
01
Overview
ZenoParticle CH-100 is a second-generation particulate vaccine adjuvant developed by Zenogen Pharma (a subsidiary of ZENOAQ Holdings). It is composed of biodegradable, micronized chitosan polysaccharide particles designed to enhance both humoral and cellular immune responses. The adjuvant functions by activating innate immune pathways, including STING-dependent and -independent mechanisms, which leads to persistent antibody production and improved T-cell responses. Preclinical research has demonstrated that ZenoParticle CH-100 is less irritating at injection sites compared to traditional oil-based adjuvants and exhibits superior performance compared to aluminum-based adjuvants (Alum). It has been evaluated in animal models with various antigens, including SARS-CoV-2 spike RBD and ovalbumin (OVA). Currently, the product is available for research use only and is not approved for human diagnostic or therapeutic use.
- Brand names
- ZenoParticle CH-100
- Other names
- ZenoParticle CH100ZenoParticle CH-100 vaccine adjuvantmicronized chitosan particles
02
Targets
CLEC9A (C-type lectin domain family 9 member A)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on ZenoParticle CH-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZenoParticle CH-100.